Relmada Therapeutics Shifts Focus After Study Discontinuation

TipRanksDec 9, 2024 08:35 ET

Relmada Therapeutics Exploring Sale After Lead Program Failure

WSJDec 9, 2024 07:59 ET

Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives

Quiver QuantitativeDec 9, 2024 07:41 ET

Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives

ReutersDec 9, 2024 07:32 ET

Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease

ReutersDec 9, 2024 07:32 ET

Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017

ReutersDec 9, 2024 07:30 ET